Contributions to the treatment of primary liver cancer. 4'-epidoxorubicin and cisplatin studied in hepatocarcinoma cell cultures and in partially hepatectomized rats.
Hall
K S
KS
Department of Clinical Pharmacology, Rikshospitalet, University of Oslo, Norway.
D000818:Animals; D002945:Cisplatin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004351:Drug Resistance; D015251:Epirubicin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats; D014407:Tumor Cells, Cultured
D015251:Epirubicin; D002945:Cisplatin